104
Views
4
CrossRef citations to date
0
Altmetric
Reviews

Therapeutic strategies for treatment of pulmonary lymphangioleiomyomatosis

, PhD MBA FCPP
 

Abstract

Introduction: Pulmonary lymphangioleiomyomatosis (LAM) is a rare progressive lung disease affecting almost exclusively women. Neoplastic growth of atypical smooth muscle-like cells in the lung induces destruction of lung parenchyma leading to the formation of lung cysts, rupture of which results in spontaneous pneumothorax. LAM occurs sporadically or in association with inherited hamartoma syndrome tuberous sclerosis complex. Progression of LAM often results in loss of pulmonary function and death. Increasing understanding of neoplastic LAM cell growth is driving the development of therapeutic approaches targeting the disease progression.

Areas covered: This review provides background to understand the rationale for current treatments used in patients with LAM, to critically appraise the evidence for these treatments and to discuss future treatment approaches. The literature review includes publications from PubMed and clinicaltrials.gov/.

Expert opinion: Targeting mTOR activation with rapamycin analogs sirolimus and everolimus is awaiting approval by the US FDA for treatment of LAM. A number of other treatment options have been investigated and are currently tested in clinical trials to target LAM cell survival and metastasis. Key remaining and poorly understood areas for development and validation of therapeutic targeting in LAM are destruction of lungs, pathological lymphangiogenesis and hormonal regulation. Future will reveal whether they could be targeted therapeutically.

Acknowledgements

The author thanks Ms Kelci Holman for help with text and Tables; Ms Darya Volgina for help with Table 1. Dr VP Krymskaya's work is supported in part by grants from the NIH/NHLBI RO1 HL090829 (V.P.K.), RO1 HL110551 (V.P.K.), and RO1 HL114085 (V.P.K.).

Notes

This box summarizes key points contained in the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.